Windward Bio prices $175 million Nasdaq IPO
SNY•Windward Bio priced a $175 million Nasdaq IPO, excluding the greenshoe option. A concurrent $50 million private placement with Sanofi brings expected gross proceeds from both transactions to $225 million.
1. IPO and placement
Windward Bio priced a $175 million Nasdaq IPO, excluding the greenshoe option. A concurrent $50 million private placement with Sanofi brings expected gross proceeds from both transactions to $225 million.
2. Company and lead candidate
Windward develops ultra-long-acting antibodies for respiratory and dermatological diseases. Its lead candidate, WIN378, is designed for twice-yearly dosing; the company reported positive interim asthma results for WIN378 and initiated Phase 3 in September 2026.




